Exit

NovoEd passes acquisition test
Occupational learning tool developer NovoEd, based on research at Stanford, has been bought by Devonshire Investors after raising $4.8m of series A capital in 2014.
Turnitin marks Gradescope for acquisition
UC Berkeley’s SkyDeck accelerator has secured an exit as schoolwork assessment technology developer Gradescope was acquired by Turnitin.
Orchard to orchestrate $173m IPO
The UCL Technology Fund is in line for an exit from gene therapy developer Orchard Therapeutics, which has raised more than $290m in equity funding.
Sutro seals $86m IPO
Sutro Biopharma, an immunotherapy developer commercialising technology created at Stanford University, has floated on the Nasdaq Global Market.
Principia achieves $122m IPO
Principia Biopharma, whose drug discovery platform is based on research at UCSF, has completed a $122m initial public offering after underwriters exercised their greenshoe option.
Asarina diagnoses listing
Karolinska Development has celebrated an exit as Umeå spinout Asarina Pharma went public in Sweden after raising $16.3m in its initial public offering.
VitalSource exercises Acrobatiq acquisition
Educational content creation platform Acrobatiq spun out from Carnegie Mellon University in 2015 and had been backed by the university's Carnegie Innovations division.
Investcorp cultivates Softgarden
Softgarden, a spinout of Saarland University, has been acquired for Investcorp Technology Partners for an undisclosed sum.

Other News

Sutro starts IPO proceedings
A month after Sutro closed an $85.4m series E round, the cancer drug developer, based on research at Stanford, has filed for a $75m initial public offering.
10x engineers Epinomics acquisition
Epigenomics services provider Epinomics, co-founded by Stanford University faculty and alumni, has been bought by 10x Genomics in a transaction which enables StartX to exit.
Dexcom collects TypeZero
Ascentage approaches Hong Kong IPO
Ascentage Pharma, based on research at University of Michigan, has filed to list in Hong Kong having raised about $235m in funding.
Principia Biopharma primes $86m IPO
Principia Biopharma, whose drug discovery platform is based on research at UCSF, has filed for an $86.3m initial public offering having raised $50m earlier this month.
Serum braces for Vakzine acquisition

Editor's Picks

Big deal: Novo pens $800m Ziylo acquisition
Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.
Big deal: Nucana and Nightstar race to public markets
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
Big deal: Allied-Bristol Life Sciences
Allied Minds and Bristol-Myers Squibb are joining forces to foster biopharmaceutical research at US universities.
Samsung's lights up spin-outs
test reg

Login

Not yet subscribed?

See your subscription offers here